Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- GlaxoSmithKline Plc (NYSE:GSK) has submitted a marketing application to the FDA seeking approval for PRIORIX for use in active immunization against infection by measles, mumps, and rubella (MMR).
- GSK MMR vaccine is available in Europe since 1997. The safety of PRIORIX was evaluated in six clinical studies. Total of 17,393 subjects received at least one dose of either PRIORIX or Measles, Mumps, and Rubella Virus Vaccine, Live (M-M-RII) from Merck & Co Inc (NYSE:MRK).
- The efficacy of PRIORIX was demonstrated based on comparative immunogenicity data with M-M-RII.
- The most commonly reported adverse reactions were pain, redness, swelling, loss of appetite, irritability, drowsiness, and fever.
- If approved, PRIORIX would provide US healthcare providers with another MMR vaccine choice.
- GSK is also seeking approval for PRIORIX administration as a second dose to individuals who received another MMR vaccine.
- Price Action: GSK shares are up 0.3% at $40.25 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!